Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (181-190 of 283) with videos related to

Pageof 29
Sort By:
Haematologica|June 29, 2014
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myelomaDominik Dytfeld, Jagoda Jasielec, Kent A Griffith, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
<i>LINC01432</i> binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapyRicha Mishra, Prasanth Thunuguntla, Alani Perkin, et al.
Blood Cancer Journal|May 13, 2021
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumabJoseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, et al.
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Leukemia & Lymphoma|July 24, 2018
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 casesArtur Jurczyszyn, Julio Davila, K Martin Kortüm, et al.
Leukemia & Lymphoma|January 20, 2021
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromesEric Huselton, Michael P Rettig, Theresa Fletcher, et al.
Plos Computational Biology|August 8, 2014
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolutionChristopher A Miller, Brian S White, Nathan D Dees, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaNina Shah, Jack Aiello, David E Avigan, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Defining the RNA Modification Landscape of Multiple Myeloma Reveals METTL3-Dependent m <sup>6</sup> A Regulation of <i>NEAT1</i>Prasanth Thunuguntla, Dhanusha Duraiyan, Catheryn Sizemore, et al.
Pageof 29

Showing results (181-190 of 283) with videos related to

Sort By:
Pageof 29
Haematologica|June 29, 2014
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myelomaDominik Dytfeld, Jagoda Jasielec, Kent A Griffith, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
<i>LINC01432</i> binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapyRicha Mishra, Prasanth Thunuguntla, Alani Perkin, et al.
Blood Cancer Journal|May 13, 2021
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumabJoseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, et al.
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Leukemia & Lymphoma|July 24, 2018
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 casesArtur Jurczyszyn, Julio Davila, K Martin Kortüm, et al.
Leukemia & Lymphoma|January 20, 2021
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromesEric Huselton, Michael P Rettig, Theresa Fletcher, et al.
Plos Computational Biology|August 8, 2014
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolutionChristopher A Miller, Brian S White, Nathan D Dees, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaNina Shah, Jack Aiello, David E Avigan, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Defining the RNA Modification Landscape of Multiple Myeloma Reveals METTL3-Dependent m <sup>6</sup> A Regulation of <i>NEAT1</i>Prasanth Thunuguntla, Dhanusha Duraiyan, Catheryn Sizemore, et al.
Pageof 29